RT Journal Article
SR Electronic
T1 Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.24.20100990
DO 10.1101/2020.05.24.20100990
A1 Assennato, Sonny M
A1 Ritchie, Allyson V
A1 Nadala, Cesar
A1 Goel, Neha
A1 Zhang, Hongyi
A1 Datir, Rawlings
A1 Gupta, Ravindra K
A1 Curran, Martin D
A1 Lee, Helen H
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.05.24.20100990.abstract
AB Nucleic acid amplification for the detection of SARS-CoV-2 RNA in respiratory samples is the standard method for diagnosis. These tests are centralised and therefore turnaround times can be 2-5 days. Point-of-care testing with rapid turnaround times would allow more effective triage in settings where patient management and infection control decisions need to be made rapidly.Inclusivity and specificity of the SAMBA II SARS-CoV-2 assay was determined by in silico analyses of the primers and probes. Analytical and clinical sensitivity and specificity of the SAMBA II SARS-CoV-2 Test was evaluated for analytical sensitivity and specificity. Clinical performance was evaluated in residual clinical samples compared to the Public Health England reference tests.The limit of detection of the SAMBA II SARS-CoV-2 Test is 250 cp/mL and is specific for detection of 2 regions of the SARS-CoV-2 genome. The clinical sensitivity was evaluated in 172 clinical samples provided by the Clinical Microbiology and Public Health Laboratory, Addenbrooke’s Hospital, Cambridge (CMPHL), which showed a sensitivity of 98.9% (95% CI 94.03-99.97%), specificity of 100% (95% CI 95.55-100%), PPV of 100% and NPV of 98.78% (92.02-99.82%) compared to testing by CMPHLSAMBA detected 3 positive samples that were initially negative by PHE Test. The data shows that the SAMBA II SARS-CoV-2 Test performs equivalently to the centralised testing methods with a much quicker turnaround time. Point of care testing, such as SAMBA, should enable rapid patient management and effective implementation of infection control measures.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: RKG is funded by Wellcome Senior Fellowship In Clinical Science award no WT108082AIA and has received personal fees form ViiV, Gilead and UNMOVIS during the conduct of the study; AVR, SMA, CN, NG and HHL are employees of Diagnostics for the Real World Ltd, which manufactures and markets the SAMBA II test platform. AVR, SMA and HHL are also inventors on patents related to the SAMBA technology. RD, HZ and MDC have no conflicts to declare. Clinical TrialNA - Retrospective study - all samples were anonymised and used for assay validationFunding StatementRKG was funded by Wellcome Senior Fellowship In Clinical Science award no WT108082AIA during the course of the work. Other authors did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Surplus samples obtained from patients known to be symptomatic for COVID-19 and submitted to the Public Health England Cambridge Laboratory for routine testing were retrieved before being discarded. These samples were rendered anonymous and provided blinded for the purpose of test validation. CMPHL and NHS Research Ethics Committee have permitted the use of residual samples in this manner, strictly for the purpose of diagnostic assay validation [16]. The evaluation was carried out in accordance with The Use of Human Organs and Tissue act [17].All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA